Skip to content

US · AVR · MEDICAL - DEVICES

Anteris Technologies Global Corp. (AVR) intrinsic value and stock valuation

$4.99as of 2026-11-21 · Mkt cap 866.34M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Anteris Technologies Global Corp. DCF and intrinsic value

InvestorsCraft values AVR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from AVR’s statements →

Anteris Technologies Global Corp. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Eagan, MN 55121 anteristech.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$1.91M-18.9% 5y CAGRd
20202025
Net income
-$-94.14M
20202025
Free cash flow
-$-79.76M
20202025
Total equity
-$-250K
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$1.91M$2.7M$2.73M$3.2M$5.83M
Operating income-$-93.89M-$-78.37M-$-48.14M-$-31.11M-$-16.86M
Net income-$-94.14M-$-76.29M-$-46.02M-$-30.56M-$-17.17M
EPSd-$-3.99M-$-3.77M-$-1.28M-$-850.31K-$-477.74K
Operating cash flow-$-77.8M-$-61.24M-$-34.63M-$-29.42M-$-14.44M
Capital expenditure-$-1.95M-$-2.27M-$-2.39M-$-1.67M-$-580K
Free cash flow-$-79.76M-$-63.51M-$-37.03M-$-31.08M-$-15.02M
Total assets$23M$80.7M$30.5M$16M$21.4M
Total debt$2.28M$1.4M$1.6M$950K$4.14M
Net debt-$-10.29M-$-69.06M-$-19.43M-$-8.34M-$-11.32M
Total equity-$-250K$62.7M$18.9M$9.03M$10.5M
Cash and short-term investments$12.6M$70.5M$21M$9.29M$15.5M
Income statement
20252024202320222021
Revenue$1.91M$2.7M$2.73M$3.2M$5.83M
Cost of revenue$2.23M$1.44M$1.86M$2.9M$3.93M
Gross profit-$-320K$1.27M$880K$300K$1.91M
Research and development expenses$69.1M$51.5M$31M$17.6M$9.99M
Selling, general and administrative expenses$24.5M$0.00$17.1M$15.2M$9.14M
Other expenses$0.00$28.2M$950K-$-1.39M-$-360K
Operating expenses$93.6M$79.6M$49M$31.4M$18.8M
Cost and expenses$95.8M$81.1M$50.9M$34.3M$22.7M
Interest income$710K$0.00$430K$210K$70K
Interest expense$70K$80K$70K$650K$1.03M
Depreciation and amortization$1.66M$1.51M$1.16M$770K$640K
Ebitda-$-92.49M-$-74.38M-$-45.54M-$-29.14M-$-15.5M
Operating income-$-93.89M-$-78.37M-$-48.14M-$-31.11M-$-16.86M
Total other income/expenses, net-$-330K$2.4M$1.38M$550K-$-310K
Income before tax-$-94.22M-$-75.97M-$-46.76M-$-30.56M-$-17.17M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-94.14M-$-76.29M-$-46.02M-$-30.56M-$-17.17M
Weighted average shares outstanding$23.6M$20.3M$35.9M$35.9M$35.9M
Weighted average diluted shares outstanding$23.6M$20.3M$35.9M$35.9M$35.9M
Balance sheet
20252024202320222021
Cash and short-term investments$12.6M$70.5M$21M$9.29M$15.5M
Net receivables$30K$380K$1.85M$1.51M$1.85M
Inventory$730K$510K$440K$360K$550K
Total current assets$15.7M$74.7M$24.2M$12.2M$18.8M
Property, plant and equipment, net$7.26M$5.86M$5.48M$3.14M$1.92M
Goodwill and intangible assets$70K$190K$410K$610K$760K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$7.32M$6.05M$6.31M$3.75M$2.68M
Total assets$23M$80.7M$30.5M$16M$21.4M
Accounts payable$11.1M$5.89M$3.14M$1.73M$2.23M
Short-term debt$580K$750K$1.34M$1.03M$3.83M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$21.4M$16.6M$9.46M$6.05M$10.2M
Long-term debt$1.7M$650K$930K$440K$310K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.88M$1.46M$2.17M$910K$710K
Capital lease obligations$1.68M$1.39M$1.6M$950K$760K
Total liabilities$23.3M$18M$11.6M$6.95M$10.9M
Common stock$0.00$0.00$217.3M$169.8M$141.5M
Retained earnings-$-370.53M-$-276.39M-$-200.1M-$-154.07M-$-123.51M
Accumulated other comprehensive income (loss)-$-10.28M-$-10.89M-$-9.56M-$-9.94M-$-7.75M
Total equity-$-250K$62.7M$18.9M$9.03M$10.5M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$2.28M$1.4M$1.6M$950K$4.14M
Net debt-$-10.29M-$-69.06M-$-19.43M-$-8.34M-$-11.32M
Cash flow statement
20252024202320222021
Net income-$-94.22M-$-76.29M-$-46.76M-$-30.56M-$-17.17M
Depreciation and amortization$1.66M$1.51M$1.16M$770K$640K
Stock-based compensation$7.78M$0.00$5.76M$2.94M$250K
Change in working capital$6.26M$6.69M$3.99M-$-1.75M$980K
Accounts receivable-$-520K-$-910K-$-350K-$-530K$90K
Inventory$360K-$-70K-$-90K$190K-$-20K
Accounts payable$6.42M$7.67M$0.00$0.00$0.00
Net cash provided by operating activities-$-77.8M-$-61.24M-$-34.63M-$-29.42M-$-14.44M
Investments in property, plant and equipment-$-1.95M-$-2.27M-$-2.39M-$-1.57M-$-570K
Acquisitions, net$0.00$0.00-$-210K$0.00$0.00
Net cash used for investing activities-$-600K-$-2.28M-$-2.58M-$-990K-$-890K
Common stock issued$23M$115.7M$52.8M$25.3M$26.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$20.6M$112.8M$49.3M$23.3M$27.4M
Net change in cash-$-57.88M$49.4M$11.7M-$-6.1M$12.1M
Cash at end of period$12.6M$70.5M$21.1M$9.35M$15.5M
Operating cash flow-$-77.8M-$-61.24M-$-34.63M-$-29.42M-$-14.44M
Capital expenditure-$-1.95M-$-2.27M-$-2.39M-$-1.67M-$-580K
Free cash flow-$-79.76M-$-63.51M-$-37.03M-$-31.08M-$-15.02M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Anteris Technologies Global Corp.

        Anteris Technologies Global Corp. is a structural heart innovator dedicated to discovering, developing, and bringing to market medical devices that enhance the well-being of patients grappling with aortic stenosis. The company's premier offering is the DurAVR transcatheter heart valve system, a pioneering transcatheter aortic valve engineered to treat aortic stenosis by precisely emulating the performance of a healthy human aortic valve. Beyond this, Anteris develops ADAPT anti-calcification tissue, a unique preparation that transforms xenograft tissue into robust bioscaffolds. These bioscaffolds are designed to simulate human tissue for various surgical repairs, notably in aortic valve replacement. Additionally, the ComASUR delivery system, a physician-designed balloon-expandable apparatus, features a reinforced, steerable catheter. This allows for highly accurate navigation through cardiac anatomy in a controlled manner, thereby mitigating potential damage to the aorta. Founded in 1999, Anteris Technologies Global Corp. operates out of Toowong, Australia.

        CEO
        Wayne Geoffrey Paterson
        Employees
        174
        Beta
        0.73

        Explore

        Frequently asked questions

        What is the intrinsic value of Anteris Technologies Global Corp. (AVR)?

        Anteris Technologies Global Corp. (AVR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AVR undervalued?

        AVR trades at a price of $4.99 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.